Several preclinical models of bone diseases including multiple myeloma (MM), osteoporosis and rheumatoid arthritis have shown that DKK1 knockdown, inhibition or neutralization using specific antibodies improved bone weight, mineral content, mineral density, and volume thus reducing the overall bone erosion [74,75,76,77,78]. The gene discussed is DKK1; the disease is plasma cell myeloma.